// App-Quantinova.ai

PB1358 : Fostamatinib as Second-Line Therapy for ITP and in Earlier Stage ITP Patients

Researchers

Presenter

  • W. Ghanima

Principal Investigators

  • N. Cooper

  • R. Boccia

  • M. Boxer

  • Q. Hill

  • M. Sholzberg

  • M. Tarantino

  • Y. Kreychman

  • V. Markovtsov

  • S. Tong

  • J. Bussel

Medical Centers

  • Østfold Hospital Trust, Dept. of Research, Sarpsborg, Norway

  • Institute of Clinical Medicine, Department of Hematology, Sarpsborg, Norway

  • Imperial College Healthcare NHS Trust St Marys Hospital, London, United Kingdom

  • Center for Cancer and Blood Disorders,Bethesda,Vereinigte Staaten

  • Arizona Oncology Associates,Tuscon, AZ,United States

  • St. James' Hospital, Dept. of Haematology, Leeds, United Kingdom

  • St. Michael's Hosp, Toronto, ON, Canada

  • The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine‐Peoria, Peoria, USA

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Rigel Pharmaceuticals, Inc., Dept. of Medical Affairs, South San Francisco, United States

  • Pediatrics, Weill Cornell Medical College, New York, New York, United States

Locations

  • Norway

  • United Kingdom

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Fostamatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved